Loading clinical trials...

Physiotherapist in the Emergency Department | Clinical Trials | Clareo Health

COMPLETED

Physiotherapist in the Emergency Department

Physiotherapist in the Emergency Department : What Impact Does the Intervention of the Physiotherapist Have on the Care Pathway of the Elderly Person Who Falls?

NCT05753319•Nantes University Hospital

View on ClinicalTrials.gov

Summary

This study aims to evaluate the impact of assessment and early physiotherapy management on the care pathway of the elderly person who falls, their length of stay in hospital and their fall recurrence rate.

Eligibility

Age

75 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients aged 75 and over
•2. Patients admitted to emergency for falls.
•3. Clinically stable patient who may benefit from a gait assessment or fall risk assessment
•4. Patients able to understand the protocol and not verbally object to participation.

Exclusion Criteria

•1. Patients with limb fractures requiring surgical treatment
•2. Patients under guardianship or curatorship.
•3. Patients already included in an interventional research protocol.

Locations (1)

University Hospital of Nantes

Nantes, Loire-Atlantique, France

Key Dates

Start Date

April 6, 2023

Primary Completion Date

March 14, 2024

Completion Date

March 14, 2024

Last Updated

May 22, 2024

Enrollment

155

ACTUAL participants

Conditions

EmergenciesFall

Interventions

Physiotherapy in the emergency department after a fall

OTHER

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

RECRUITINGPHASE3

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471

Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian Cancer+5 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 22, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Physiotherapist in the Emergency Department

Inclusion Criteria

Exclusion Criteria

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Association Between Intake of Psychotropic Medications and Risk of Falls in Older Adults

Patient Perspectives of an Automated Falls-Risk Screening and Referral Tool in the Emergency Department (ED)

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry